Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COVID-19 Vaccine · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| COVID-19 Vaccine | BIOLOGICAL | Receive SOC mRNA SARS-CoV-2 vaccine IM |
| Diagnostic Laboratory Biomarker Analysis | OTHER | Correlative studies |
| Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 | BIOLOGICAL | Given IM |
COVID-19 Vaccine (GEO-CM04S1) is an investigational vaccine being studied for the prevention of COVID-19 infection in patients with blood cancers, including leukemia, lymphoma, and plasma cell myeloma. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
COVID-19 Vaccine (GEO-CM04S1) is being developed by GeoVax Labs, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GOVX. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in patients with hematologic malignancies.
COVID-19 Vaccine (GEO-CM04S1) is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is actively enrolling participants, though recruitment is not yet complete.
COVID-19 Vaccine (GEO-CM04S1) is being evaluated in one active Phase 2 clinical trial, identified as NCT04977024. This trial compares the vaccine to an mRNA SARS-CoV-2 vaccine in patients with blood cancers, with an enrollment target of 63 participants.
Yes, COVID-19 Vaccine (GEO-CM04S1) is also known as GEO-CM04S1. The vaccine is being studied under this alternative name in clinical trial registries and scientific literature. Both names refer to the same investigational vaccine candidate developed by GeoVax Labs.